Twist Bioscience Corporation research snapshot
TWST AI stock analysis reads Twist Bioscience as a high-growth synthetic biology platform with a semiconductor-based DNA writing process, expanding NGS tools and protein solutions, and a company-guided path to adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. At the August 3, 2026 data cutoff, TWST closed near $91.55 on July 31, 2026, with a verified market capitalization near $5.70 billion. The stock has rallied about 189% year to date on AI-enabled drug discovery demand, an AWS partnership for Amazon Bio Discovery, and stronger revenue growth, but it remains pre-profit with a Price/Sales multiple near 13.9x. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$91.55
Market cap
$5.70 billion
AI score
64 / 100
Rating
High-growth DNA synthesis platform nearing adjusted EBITDA breakeven
Trend status
Uptrend intact after a 189% YTD rally, consolidating below the 52-week high with high beta
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Twist writes synthetic DNA on silicon at scale for drug discovery, diagnostics, NGS, and research. Customers pay for speed, accuracy, and throughput that traditional column-based methods cannot match, and the platform has delivered 13 consecutive quarters of sequential revenue growth. | Medium-high |
| Moat | The moat comes from a semiconductor-based synthesis platform with structural cost, scale, and speed advantages, plus switching costs in validated NGS panels and antibody workflows. Deep-pocketed competitors such as IDT (Danaher), GenScript, and Agilent keep the moat narrow but durable. | Medium |
| Management | Founder and CEO Emily Leproust leads with strong scientific credibility. Management raised fiscal 2026 guidance, expanded gross margin above 50%, closed a securities litigation settlement, and targets adjusted EBITDA breakeven in Q4 fiscal 2026. Capital allocation prioritizes R&D and capacity. | Medium-high |
| Financial trend | Revenue grew from $132M in FY2021 to $376.57M in FY2025 and $409.48M in TTM, with gross margin rising to 52.07%. Net loss narrowed from -$208.73M in FY2024 to -$77.67M in FY2025, but the company remains pre-profit with negative free cash flow. | Medium-high |
| Valuation | At $91.55, TWST trades at 13.92x TTM revenue and 12.50x book value. The P/S multiple is elevated for a pre-profit company but reflects accelerating growth, AI drug discovery momentum, and the stated path to adjusted EBITDA breakeven. | Medium |
| Technical trend | Price holds an uptrend well above the 50-day moving average near $83.51 and the 52-week low of $23.30, but has consolidated below the 52-week high of $105.47. RSI near 53 is neutral after pulling back from overbought, suggesting consolidation rather than breakdown. | Medium |
| Risk level | Main risks include pre-profit status and cash burn, reliance on AI drug discovery order flow, customer concentration in NGS, short interest near 22.7% of shares outstanding, competition from larger life science tools firms, and high beta near 2.11 amplifying moves. | Medium-high |
| AI confidence | High for descriptive facts and audited calculations, medium for forward scenarios and chart levels. | High data confidence |
| Investment certainty | Low to medium certainty. The page frames scenarios and monitoring rules, not a buy or sell instruction. | Low to medium |
TWST AI stock forecast
The TWST AI stock forecast uses scenario math around the $91.55 quote and the fiscal 2026 revenue guidance of $442M to $447M. The framework produced a bearish area near $55 to $70, a base area near $85 to $100, and a bullish area near $115 to $130, reflecting the wide uncertainty range for a pre-profit growth company.
$115 to $130
More likely if the company reaches adjusted EBITDA breakeven in Q4 fiscal 2026 as guided, DNA synthesis and protein solutions keep growing above 20%, NGS returns to 20% growth, and AI drug discovery demand from big tech partners keeps expanding the order book.
$85 to $100
More likely if Twist delivers the $442M to $447M fiscal 2026 revenue guidance, holds gross margin near 52%, reaches adjusted EBITDA breakeven around the guided quarter, and the P/S multiple stabilizes near 12x to 14x as consolidation replaces the initial rally.
$55 to $70
More likely if AI drug discovery orders decelerate, cash burn continues without a confirmed profitability quarter, competition from IDT or Danaher intensifies, or the market rotates away from pre-profit growth stocks and compresses the multiple toward 10x.
TWST AI technical analysis
TWST AI technical analysis shows a stock in an uptrend that is consolidating after a large year-to-date rally as of the July 31, 2026 close. Price sits near $91.55, above the 50-day moving average of $83.51 and well above the 200-day moving average of $52.58. The 52-week high of $105.47 is the key overhead resistance, and RSI near 53 suggests momentum has cooled from overbought into neutral.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $91.55 | Closing quote snapshot from July 31, 2026 on NASDAQ, with after-hours around $90.10. |
| Near support | $83.51 | The 50-day moving average, which has acted as support during the recent uptrend. |
| Deeper support | $78 to $82 | A former breakout zone from early 2026 that may hold on a deeper pullback. |
| Major trend support | $52.58 | The 200-day moving average, the long-term trend reference for the current structure. |
| Near resistance | $93.57 | The July 31 intraday high, the first overhead hurdle after the recent consolidation. |
| Round resistance | $100 | Psychological round-number resistance between current price and the 52-week high. |
| Major resistance | $105.47 | The 52-week high is the dominant overhead resistance after the 189% YTD rally. |
| Momentum | RSI near 53 | The 14-day RSI near 53 is neutral after cooling from overbought, suggesting consolidation rather than exhaustion. |
| Volume | Average volume near 1.72 million shares | Yahoo Finance lists average volume near 1.72 million shares, with the 20-day average near 1.36 million, useful for judging breakout quality. |
| Volatility | Beta of 2.11 | TWST carries a beta near 2.11, meaning it tends to move more than twice the market in either direction. |
| Invalidation | Close below $83.51 | A decisive close below the 50-day moving average would weaken the uptrend thesis and open the door to the $78 to $82 zone. |
TWST AI trading strategy
The TWST AI trading strategy is a rules-based research framework for monitoring a high-growth DNA synthesis stock with a near-term profitability catalyst. It is not personal advice and should be paired with fresh chart data, the fiscal Q3 2026 earnings report, filings, position sizing, and a defined invalidation level.
Watch for TWST to hold above the $83.51 moving average support, then clear the $100 to $105 area on elevated volume. A sustained move toward new highs would require continued revenue acceleration and confirmation of the Q4 fiscal 2026 adjusted EBITDA breakeven target.
A close below $83.51 or a failed attempt at the 52-week high after the fiscal Q3 earnings update should invalidate the near-term momentum setup.
If TWST pulls back toward the $78 to $82 zone without a negative fundamental catalyst, monitor for stabilization and volume contraction before considering re-entry. The 50-day moving average near $83.51 is the first level to watch on a shallow pullback.
Do not average down without a maximum loss rule because pre-profit biotech stocks can gap down sharply on missed guidance, competitive news, or sector rotation, and short interest near 22.7% of shares can amplify downside moves.
Track the fiscal 2026 revenue guidance of $442M to $447M, gross margin trajectory near 52%, the Q4 adjusted EBITDA breakeven milestone, NGS return to 20% growth, AI drug discovery order flow, cash position, and the August 3, 2026 fiscal Q3 earnings report.
Reduce confidence if revenue growth decelerates, adjusted EBITDA breakeven is pushed out, cash burn accelerates, or management signals slower AI-driven discovery adoption.
Investment research summary
Twist Bioscience writes synthetic DNA on silicon wafers. Customers pay because they need custom genes, NGS panels, protein solutions, and antibody tools that are faster, more accurate, and more scalable than traditional synthesis methods, with AWS even naming Twist a wet lab partner for its AI drug discovery application.
The moat is technology-based but not absolute. Twists silicon platform offers throughput and cost advantages over column-based methods, and validated workflows create switching costs. However, deep-pocketed competitors such as IDT (Danaher), GenScript, and Agilent can invest to close the gap.
The thesis fails if AI drug discovery orders decelerate, DNA synthesis becomes more commoditized, competitors match Twist technology, revenue growth stalls before reaching profitability, cash burn requires dilutive financing, or the Q4 fiscal 2026 adjusted EBITDA breakeven target slips.
Founder and CEO Emily Leproust brings strong scientific and operational experience. The team has raised fiscal 2026 guidance, expanded gross margin above 50%, and reached a securities litigation settlement. Key risks include key-person dependence and executing the transition from growth-at-all-costs to profitability.
Synthetic biology and AI-enabled drug discovery are in a long-term secular growth phase. Declining DNA synthesis costs and big tech investment in wet lab partnerships enable new applications in therapeutics, diagnostics, agriculture, materials, and data storage. Twist is positioned as a leading platform, but the market is still early-stage.
At roughly 13.9x TTM revenue and with the stock up about 189% year to date, TWST trades at a premium that reflects long-duration synthetic biology optionality and AI drug discovery momentum. Margin of safety is limited at current levels, with the stock requiring continued execution and sector enthusiasm to sustain the multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TWST price | $91.55 (July 31, 2026 close) | Yahoo Finance quote snapshot | August 3, 2026 |
| Market capitalization | $5.70 billion, verified as $91.55 x 62.27 million shares | financial_rigor.py market cap verification | August 3, 2026 |
| Revenue (TTM) | $409.48 million, cross-checked across StockAnalysis and Yahoo Finance | StockAnalysis / Yahoo Finance financials | August 3, 2026 |
| Net income (TTM) | -$81.28 million, cross-checked across StockAnalysis and Yahoo Finance | StockAnalysis / Yahoo Finance financials | August 3, 2026 |
| EPS (TTM) | -$1.33 | StockAnalysis statistics | August 3, 2026 |
| Gross margin (TTM) | 52.07% | StockAnalysis financials | August 3, 2026 |
| Cash and cash equivalents | $171.67 million | StockAnalysis balance sheet | August 3, 2026 |
| Free cash flow (TTM) | -$95.04 million (operating cash flow -$55.59M less capex -$39.45M) | StockAnalysis cash flow | August 3, 2026 |
| Price to sales ratio | 13.92x TTM revenue (Yahoo lists 13.61x) | StockAnalysis / financial_rigor.py calculation | August 3, 2026 |
| Price to book ratio | 12.50x | StockAnalysis statistics | August 3, 2026 |
| Shares outstanding | 62.27 million | StockAnalysis share statistics | August 3, 2026 |
| 52-week range | $23.30 to $105.47 | Yahoo Finance statistics | August 3, 2026 |
| Beta | 2.11 | StockAnalysis statistics | August 3, 2026 |
| Fiscal 2026 revenue guidance | $442M to $447M, with adjusted EBITDA breakeven expected in Q4 fiscal 2026 | Twist Bioscience Q2 fiscal 2026 earnings call, May 4, 2026 | August 3, 2026 |
| Analyst consensus target | Buy rating from 11 analysts, $92.50 average, $98.50 median, range $36 to $120 (Leerink $110, Canaccord $120, Guggenheim $107, Barclays $95) | StockAnalysis forecast / TipRanks | August 3, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell TWST stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Always verify current filings, prices, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
